Sorafenib is a multikinase inhibitor that blocks several targets including Fms-like tyrosine kinase-3 (FLT3), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), c-Kit and B-RAF signaling [5] in both tumor cells and the surrounding endothelial cells [6,7,8]. Here, FLT3 is linked to neoplasm.